HK Stock MarketDetailed Quotes

02607 SH PHARMA

Watchlist
  • 11.300
  • -0.240-2.08%
Market Closed Mar 28 16:08 CST
41.85BMarket Cap8.35P/E (TTM)

SH PHARMA Key Stats

All
YOY yoy
Hide blank lines yoy
(Q9)Sep 30, 2023
(Q6)Jun 30, 2023
(Q3)Mar 31, 2023
(FY)Dec 31, 2022
(Q9)Sep 30, 2022
(Q6)Jun 30, 2022
(Q3)Mar 31, 2022
(FY)Dec 31, 2021
(Q9)Sep 30, 2021
(Q6)Jun 30, 2021
Turnover
13.11%197.51B
18.70%132.59B
16.39%66.23B
7.49%231.98B
8.47%174.61B
6.15%111.71B
10.27%56.9B
12.46%215.82B
14.72%160.97B
20.73%105.24B
Operating income
13.11%197.51B
18.70%132.59B
16.39%66.23B
7.49%231.98B
8.47%174.61B
6.15%111.71B
10.27%56.9B
12.46%215.82B
14.72%160.97B
20.73%105.24B
Operating expenses
-14.22%-173.55B
-19.50%-115.53B
-16.19%-57.59B
-7.59%-201.49B
-9.10%-151.93B
-5.98%-96.68B
-11.02%-49.57B
-13.38%-187.28B
-15.90%-139.26B
-23.19%-91.23B
Gross profit
5.67%23.96B
13.51%17.06B
17.80%8.63B
6.81%30.49B
4.45%22.68B
7.26%15.03B
5.41%7.33B
6.79%28.54B
7.65%21.71B
6.88%14.01B
Selling expenses
-1.29%-10.47B
-13.81%-7.73B
-18.05%-3.91B
-7.22%-14.28B
-1.18%-10.34B
-7.42%-6.79B
-4.23%-3.31B
-9.53%-13.32B
-9.56%-10.22B
-3.34%-6.32B
Administrative expenses
-11.62%-4.19B
-19.00%-2.76B
-15.70%-1.38B
2.95%-4.99B
-5.09%-3.76B
0.03%-2.32B
2.57%-1.19B
-8.70%-5.14B
-2.13%-3.57B
-4.38%-2.32B
Research and development expenses
-5.70%-1.47B
-26.76%-1.03B
-20.82%-540.69M
-6.29%-2.11B
-1.63%-1.39B
7.99%-809.67M
-7.95%-447.5M
-19.96%-1.99B
-31.38%-1.37B
-30.04%-880.03M
Profit from asset sales
-92.67%104.58M
-94.83%73.75M
188.72%21.78M
2,368.58%1.44B
22,234.19%1.43B
23,988.34%1.43B
7,912.76%7.54M
11.77%58.29M
463.86%6.39M
587.44%5.92M
Revaluation surplus
225.04%239.02M
675.23%196.84M
240.65%89.4M
206.18%218.74M
141.65%73.54M
171.34%25.39M
47.56%-63.56M
-276.38%-206M
-259.61%-176.57M
-134.42%-35.59M
-Changes in the fair value of other assets
225.04%239.02M
675.23%196.84M
240.65%89.4M
206.18%218.74M
141.65%73.54M
171.34%25.39M
47.56%-63.56M
-276.38%-206M
-259.61%-176.57M
-134.42%-35.59M
Impairment and provision
-15.91%-262.6M
-51.60%-270.22M
-362.28%-169.87M
-360.73%-643.93M
13.13%-226.55M
3.90%-178.24M
60.88%-36.75M
83.73%-139.76M
55.24%-260.79M
51.88%-185.47M
-Other impairment is provision
-15.91%-262.6M
-51.60%-270.22M
-362.28%-169.87M
-360.73%-643.93M
13.13%-226.55M
3.90%-178.24M
60.88%-36.75M
83.73%-139.76M
55.24%-260.79M
51.88%-185.47M
Special items of operating profit
-49.72%346.45M
-61.50%171.36M
41.47%356.49M
-59.88%926.88M
-67.03%689.04M
-76.12%445.11M
-83.73%251.99M
51.48%2.31B
100.01%2.09B
145.15%1.86B
Operating profit
-10.54%7.71B
-17.32%5.33B
23.59%2.91B
9.28%10.33B
11.48%8.62B
11.00%6.45B
-28.85%2.35B
12.19%9.45B
19.74%7.73B
34.97%5.81B
Financing cost
-15.71%-1.15B
-19.16%-773.22M
-16.64%-418.18M
-5.45%-1.31B
-7.26%-997.59M
-12.10%-648.91M
-13.43%-358.53M
-0.47%-1.25B
5.04%-930.05M
13.67%-578.87M
Special items of earning before tax
30.84%-36.96M
41.10%-24.29M
115.24%1.3M
-234.51%-206.3M
-1,031.28%-53.44M
-228.25%-41.24M
-261.75%-8.55M
-592.50%-61.67M
-102.95%-4.72M
57.60%-12.56M
Earning before tax
-13.86%6.52B
-21.26%4.53B
25.44%2.49B
8.16%8.81B
11.35%7.57B
10.36%5.76B
-33.72%1.99B
13.50%8.14B
24.13%6.8B
44.78%5.22B
Tax
1.16%-1.57B
6.45%-1.12B
-18.63%-538.85M
2.83%-1.82B
-10.54%-1.58B
-13.39%-1.19B
26.63%-454.25M
-19.04%-1.87B
-28.20%-1.43B
-45.67%-1.05B
After-tax profit from continuing operations
-17.22%4.95B
-25.14%3.42B
27.46%1.95B
11.43%6.99B
11.56%5.98B
9.59%4.56B
-35.56%1.53B
11.94%6.27B
23.09%5.36B
44.55%4.16B
Earning after tax
-17.22%4.95B
-25.14%3.42B
27.46%1.95B
11.43%6.99B
11.56%5.98B
9.59%4.56B
-35.56%1.53B
11.94%6.27B
23.09%5.36B
44.55%4.16B
Minority profit
-1.14%1.16B
-7.07%807.18M
54.77%435.4M
16.41%1.37B
33.04%1.17B
45.49%868.61M
9.10%281.31M
6.50%1.18B
16.39%879.72M
36.21%597.03M
Profit attributable to shareholders
-21.13%3.8B
-29.38%2.61B
21.31%1.52B
10.28%5.62B
7.35%4.81B
3.58%3.7B
-40.99%1.25B
13.28%5.09B
24.49%4.48B
46.05%3.57B
Basic earnings per share
-28.97%1.03
-37.17%0.71
-6.82%0.41
-10.06%1.61
-8.23%1.45
-10.32%1.13
-41.33%0.44
13.29%1.79
24.41%1.58
46.51%1.26
Diluted earnings per share
-28.97%1.03
-37.17%0.71
-6.82%0.41
-10.06%1.61
-8.23%1.45
-10.32%1.13
-41.33%0.44
13.29%1.79
24.41%1.58
46.51%1.26
Currency Unit
CNY
CNY
CNY
CNY
CNY
CNY
CNY
CNY
CNY
CNY
Accounting Standards
CAS (2007)
CAS (2007)
CAS (2007)
CAS (2007)
CAS (2007)
CAS (2007)
CAS (2007)
CAS (2007)
CAS (2007)
CAS (2007)
Audit Opinions
--
--
--
Unqualified Opinion
--
--
--
Unqualified Opinion
--
--
Auditor
--
--
--
PricewaterhouseCoopers Zhongtian Certified Public Accountants (Special General Partnership)
--
--
--
PricewaterhouseCoopers Zhongtian Certified Public Accountants (Special General Partnership)
--
--
(Q9)Sep 30, 2023(Q6)Jun 30, 2023(Q3)Mar 31, 2023(FY)Dec 31, 2022(Q9)Sep 30, 2022(Q6)Jun 30, 2022(Q3)Mar 31, 2022(FY)Dec 31, 2021(Q9)Sep 30, 2021(Q6)Jun 30, 2021
Turnover 13.11%197.51B18.70%132.59B16.39%66.23B7.49%231.98B8.47%174.61B6.15%111.71B10.27%56.9B12.46%215.82B14.72%160.97B20.73%105.24B
Operating income 13.11%197.51B18.70%132.59B16.39%66.23B7.49%231.98B8.47%174.61B6.15%111.71B10.27%56.9B12.46%215.82B14.72%160.97B20.73%105.24B
Operating expenses -14.22%-173.55B-19.50%-115.53B-16.19%-57.59B-7.59%-201.49B-9.10%-151.93B-5.98%-96.68B-11.02%-49.57B-13.38%-187.28B-15.90%-139.26B-23.19%-91.23B
Gross profit 5.67%23.96B13.51%17.06B17.80%8.63B6.81%30.49B4.45%22.68B7.26%15.03B5.41%7.33B6.79%28.54B7.65%21.71B6.88%14.01B
Selling expenses -1.29%-10.47B-13.81%-7.73B-18.05%-3.91B-7.22%-14.28B-1.18%-10.34B-7.42%-6.79B-4.23%-3.31B-9.53%-13.32B-9.56%-10.22B-3.34%-6.32B
Administrative expenses -11.62%-4.19B-19.00%-2.76B-15.70%-1.38B2.95%-4.99B-5.09%-3.76B0.03%-2.32B2.57%-1.19B-8.70%-5.14B-2.13%-3.57B-4.38%-2.32B
Research and development expenses -5.70%-1.47B-26.76%-1.03B-20.82%-540.69M-6.29%-2.11B-1.63%-1.39B7.99%-809.67M-7.95%-447.5M-19.96%-1.99B-31.38%-1.37B-30.04%-880.03M
Profit from asset sales -92.67%104.58M-94.83%73.75M188.72%21.78M2,368.58%1.44B22,234.19%1.43B23,988.34%1.43B7,912.76%7.54M11.77%58.29M463.86%6.39M587.44%5.92M
Revaluation surplus 225.04%239.02M675.23%196.84M240.65%89.4M206.18%218.74M141.65%73.54M171.34%25.39M47.56%-63.56M-276.38%-206M-259.61%-176.57M-134.42%-35.59M
-Changes in the fair value of other assets 225.04%239.02M675.23%196.84M240.65%89.4M206.18%218.74M141.65%73.54M171.34%25.39M47.56%-63.56M-276.38%-206M-259.61%-176.57M-134.42%-35.59M
Impairment and provision -15.91%-262.6M-51.60%-270.22M-362.28%-169.87M-360.73%-643.93M13.13%-226.55M3.90%-178.24M60.88%-36.75M83.73%-139.76M55.24%-260.79M51.88%-185.47M
-Other impairment is provision -15.91%-262.6M-51.60%-270.22M-362.28%-169.87M-360.73%-643.93M13.13%-226.55M3.90%-178.24M60.88%-36.75M83.73%-139.76M55.24%-260.79M51.88%-185.47M
Special items of operating profit -49.72%346.45M-61.50%171.36M41.47%356.49M-59.88%926.88M-67.03%689.04M-76.12%445.11M-83.73%251.99M51.48%2.31B100.01%2.09B145.15%1.86B
Operating profit -10.54%7.71B-17.32%5.33B23.59%2.91B9.28%10.33B11.48%8.62B11.00%6.45B-28.85%2.35B12.19%9.45B19.74%7.73B34.97%5.81B
Financing cost -15.71%-1.15B-19.16%-773.22M-16.64%-418.18M-5.45%-1.31B-7.26%-997.59M-12.10%-648.91M-13.43%-358.53M-0.47%-1.25B5.04%-930.05M13.67%-578.87M
Special items of earning before tax 30.84%-36.96M41.10%-24.29M115.24%1.3M-234.51%-206.3M-1,031.28%-53.44M-228.25%-41.24M-261.75%-8.55M-592.50%-61.67M-102.95%-4.72M57.60%-12.56M
Earning before tax -13.86%6.52B-21.26%4.53B25.44%2.49B8.16%8.81B11.35%7.57B10.36%5.76B-33.72%1.99B13.50%8.14B24.13%6.8B44.78%5.22B
Tax 1.16%-1.57B6.45%-1.12B-18.63%-538.85M2.83%-1.82B-10.54%-1.58B-13.39%-1.19B26.63%-454.25M-19.04%-1.87B-28.20%-1.43B-45.67%-1.05B
After-tax profit from continuing operations -17.22%4.95B-25.14%3.42B27.46%1.95B11.43%6.99B11.56%5.98B9.59%4.56B-35.56%1.53B11.94%6.27B23.09%5.36B44.55%4.16B
Earning after tax -17.22%4.95B-25.14%3.42B27.46%1.95B11.43%6.99B11.56%5.98B9.59%4.56B-35.56%1.53B11.94%6.27B23.09%5.36B44.55%4.16B
Minority profit -1.14%1.16B-7.07%807.18M54.77%435.4M16.41%1.37B33.04%1.17B45.49%868.61M9.10%281.31M6.50%1.18B16.39%879.72M36.21%597.03M
Profit attributable to shareholders -21.13%3.8B-29.38%2.61B21.31%1.52B10.28%5.62B7.35%4.81B3.58%3.7B-40.99%1.25B13.28%5.09B24.49%4.48B46.05%3.57B
Basic earnings per share -28.97%1.03-37.17%0.71-6.82%0.41-10.06%1.61-8.23%1.45-10.32%1.13-41.33%0.4413.29%1.7924.41%1.5846.51%1.26
Diluted earnings per share -28.97%1.03-37.17%0.71-6.82%0.41-10.06%1.61-8.23%1.45-10.32%1.13-41.33%0.4413.29%1.7924.41%1.5846.51%1.26
Currency Unit CNYCNYCNYCNYCNYCNYCNYCNYCNYCNY
Accounting Standards CAS (2007)CAS (2007)CAS (2007)CAS (2007)CAS (2007)CAS (2007)CAS (2007)CAS (2007)CAS (2007)CAS (2007)
Audit Opinions ------Unqualified Opinion------Unqualified Opinion----
Auditor ------PricewaterhouseCoopers Zhongtian Certified Public Accountants (Special General Partnership)------PricewaterhouseCoopers Zhongtian Certified Public Accountants (Special General Partnership)----

FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.

Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
HK
Overall
Symbol
Latest Price
%Chg